TITLE:
Diagnostic and Prognostic Value of Serum Tissue Polypeptide Antigen in Advanced Lung Cancer
AUTHORS:
Ahmed El Bastawisy, Mahmoud El Azzouny, Gamal Mohamed, Ahmed Awad Allah, Eman Behiry
KEYWORDS:
Lung Cancer; Clinical Trials
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.5 No.3,
March
19,
2014
ABSTRACT: Lung cancer is a lethal
malignancy, however, no serum marker is routinely
recommended till now. Prospectively two groups of patients included: Group I: Patients with advanced lung
cancer. Group II: patients with
benign lung disease as control. Serum Tissue Polypeptide Antigen (TPA) levels
were measured by ELISA technique before the first line chemotherapy. The TPA cutoff taken was 1800 pg./ml. End points were comparison of high TPA
in cases and controls and correlation between high TPA and disease progression
(PD), progression free survival (PFS) and overall survival (OS). 30 patients
with advanced lung cancer (16 non-small and 14 small cell lung cancer) and 15
patients with benign lung disease were included and followed up during the
period from October 2008 to October 2011 with median follow-up of 1.5 years.
High TPA was found in 50% of lung cancer cases compared to 26% in controls (p = 0.014). High TPA was found in 64% of cases
showing PD versus 36% normal TPA (p = 0.08). 1 year PFS in high TPA was 32% versus
39% in normal TPA, (p = 0.2). 1 year OS in high TPA was 46% versus
73% in normal TPA (p = 0.6). Serum TPA is a potential marker
for advanced lung cancer.